Catalyst

Slingshot members are tracking this event:

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SGMO

100%

Additional Information

Additional Relevant Details FDA has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I). The SB-318 IND application is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-318-1502) designed to assess the safety, tolerability and potential efficacy of SB-318 in adults with varying severities of MPS I.
http://investor.sang...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda Clearance, Ind, Zfn-media Genome, Sb-318, Sb-318-1502, Mucopolysaccharidosis Type I